Lupin Ltd
NSE: LUPIN BSE: 500257
₹2185.90
(2.65)%
Tue, 03 Feb 2026, 02:29 pm
Market Cap972.34B
PE Ratio23.14
Dividend0.56
Health Technology
Pharmaceuticals: Other
24.5KAnalysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends after 3 years are expected to be well covered by earnings (6.1x coverage).
- The company is paying a dividend however it is incurring a loss.
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Lupin's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Lupin's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Lupin's earnings are expected to grow significantly at over 20% yearly.
- Lupin's earnings growth is expected to exceed the India market average.
- Lupin's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Lupin is expected to become profitable in 1 year.
- Lupin is expected to become profitable in 3 years time.
- Lupin is expected to become profitable in 2 years.
- Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.
- An improvement in Lupin's performance (ROE) is expected over the next 3 years.
- Lupin's revenue growth is expected to exceed the India market average.
- Cash flow for Lupin is expected to increase but not above the 50% threshold in 2 years time.
- Lupin is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
- Lupin's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Lupin's revenue is expected to grow by 9.4% yearly, however this is not considered high growth (20% yearly).
health
- Lupin is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Lupin has been profitable on average in the past, therefore cash runway is not a concern.
- Lupin has been profitable on average in the past, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (34.3%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 3.6x debt.
- Lupin's cash and other short term assets cover its long term commitments.
- Lupin's level of debt (34.1%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (6% vs 34.1% today).
- Lupin is making a loss, therefore interest payments are not well covered by earnings.
- High level of physical assets or inventory.
management
- The tenure for the Lupin board of directors is about average.
- Vinita's remuneration is lower than average for companies of similar size in India.
- Vinita's compensation has been consistent with company performance over the past year, both up more than 20%.
- More shares have been bought than sold by Lupin individual insiders in the past 3 months.
- The tenure for the Lupin management team is about average.
misc
- Lupin has significant price volatility in the past 3 months.
past
- Unable to compare Lupin's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Lupin does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- It is difficult to establish if Lupin has efficiently used its assets last year compared to the IN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Lupin improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if Lupin has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- Unable to compare Lupin's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
value
- LUPIN outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- LUPIN outperformed the Market in India which returned -14.5% over the past year.
- NSEI:LUPIN is up 10% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:LUPIN is up 10% outperforming the market in India which returned 8% over the past month.
- Lupin's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Lupin's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Lupin is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Lupin is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
- Lupin is loss making, we can't compare the value of its earnings to the India market.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800